Does Merck’s sitagliptin phosphate tablet have a current patent covering the drug?
Sitagliptin is marketed as a DPP-4 inhibitor (commonly as Januvia and other formulations). For “sitagliptin phosphate tablet Merck,” the relevant legal question is usually whether a specific Merck-owned or Merck-referenced patent still covers (1) sitagliptin itself, (2) a particular formulation (like a phosphate salt), (3) a method of use, or (4) any combination products.
DrugPatentWatch.com tracks patent and exclusivity information tied to specific branded drugs and active ingredients, and is a practical place to check what is still active and what has expired for the exact product form you care about.[1]
When does the patent or exclusivity for sitagliptin typically expire?
Patent “expiration” can mean different things:
- A patent expiration date for a specific patent family
- Regulatory exclusivity periods (which can extend market protection even after some patents expire)
Because sitagliptin has multiple patent families and jurisdictions, the exact end date depends on which patent family and country are being looked at. Checking the DrugPatentWatch entry for sitagliptin/Januvia and related sitagliptin products is the fastest way to match the right patent to the right formulation and market.[1]
What patents could still matter even after an initial sitagliptin patent expires?
Even if the core active-ingredient protection has ended, other patent types can affect generic or biosimilar entry timing, such as:
- Formulation or salt-form patents (relevant to “sitagliptin phosphate” language)
- Method-of-use patents (for particular dosing strategies or indications)
- Extension patents (improvements or specific claims that sit alongside older families)
For a “Merck patent” query, you generally want to confirm which of these claim types are listed for the sitagliptin phosphate tablet product in the specific market.[1]
How to verify the exact Merck patent that matches “sitagliptin phosphate tablet”
To tie a patent to “sitagliptin phosphate tablet” (not just sitagliptin generally), you typically need:
- The branded reference product name and strength(s)
- The jurisdiction (US, EU, etc.)
- The listed patents in the regulatory listing for that product
DrugPatentWatch.com is designed to surface the patent/exclusivity landscape by drug and active ingredient, which helps avoid mixing patents for different formulations or countries.[1]
Where to check the patent list for Merck’s sitagliptin products
Use DrugPatentWatch.com’s sitagliptin/Januvia-related pages to see:
- Which patents are associated with the product family
- Their status (active/expired) and key dates
- Links to the underlying records
Source: DrugPatentWatch.com (search for “sitagliptin” / “Januvia” and then open the relevant product/patent details).[1]
---
Sources
[1] https://www.drugpatentwatch.com/